Vilacto Bio (Vilacto Bio) Cash, Cash Equivalents, Marketable Securities : $0.12 Mil (As of Jun. 2019)

View and export this data going back to 2013. Start your Free Trial

What is Vilacto Bio Cash, Cash Equivalents, Marketable Securities?

Vilacto Bio's quarterly cash, cash equivalents, marketable securities increased from Dec. 2018 ($0.13 Mil) to Mar. 2019 ($0.26 Mil) but then stayed the same from Mar. 2019 ($0.26 Mil) to Jun. 2019 ($0.12 Mil).

Vilacto Bio's annual cash, cash equivalents, marketable securities increased from Mar. 2017 ($0.02 Mil) to Mar. 2018 ($0.15 Mil) and increased from Mar. 2018 ($0.15 Mil) to Mar. 2019 ($0.26 Mil).

Vilacto Bio Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Vilacto Bio's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vilacto Bio Cash, Cash Equivalents, Marketable Securities Chart

Vilacto Bio Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

0.02

0.15

0.26

Vilacto Bio Quarterly Data
	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															0.05	0.14	0.13	0.26	0.12

Vilacto Bio Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Vilacto Bio (GREY:VIBI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Vilacto Bio Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Vilacto Bio's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vilacto Bio (Vilacto Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vilacto Bio Inc (GREY:VIBI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fabriksvej 48, Suite 2607, The Seagram Building, Naestved, DNK, 4700

Website

https://www.vilacto.com

Vilacto Bio Inc is a biotech company. It operates a fully patented Lactoactive molecule for treating conditions such as inflammatory diseases, diabetics, psoriasis, and skin issues in different levels. The company is also intended to develop Lactoactive molecule for increasing the quality of its retail and medical skin cream product as well as developing products for medical applications. Its product portfolio includes lotions, skin care creams and gels, lip balms, foot creams and oils, and others.